{"component": "clause", "props": {"groups": [{"samples": [{"hash": "dKhrW82kPmS", "uri": "/contracts/dKhrW82kPmS#patent-validity", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}, {"hash": "aOs8yIYYW0m", "uri": "/contracts/aOs8yIYYW0m#patent-validity", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}], "snippet": "Nothing in this Agreement shall be construed as a warranty or representation by Metasyn as to the validity or scope of any Metasyn Technology or Patent Rights or that the exercise of the Patent Rights will not infringe upon the rights of any Third Party. Notwithstanding the immediately preceding sentence, except as may have been previously disclosed to MKG, Metasyn is not aware that the Metasyn Technology or Patent Rights infringe upon or in any manner interfere with the patent rights or intellectual property rights of any Third Party.", "snippet_links": [{"key": "nothing-in-this-agreement", "type": "clause", "offset": [0, 25]}, {"key": "scope-of", "type": "definition", "offset": [110, 118]}, {"key": "metasyn-technology", "type": "definition", "offset": [123, 141]}, {"key": "patent-rights", "type": "definition", "offset": [145, 158]}, {"key": "the-patent", "type": "definition", "offset": [183, 193]}, {"key": "rights-of", "type": "definition", "offset": [228, 237]}, {"key": "third-party", "type": "clause", "offset": [242, 253]}, {"key": "notwithstanding-the", "type": "definition", "offset": [255, 274]}, {"key": "previously-disclosed", "type": "clause", "offset": [331, 351]}, {"key": "intellectual-property-rights", "type": "definition", "offset": [493, 521]}], "size": 5, "hash": "8f552a1ac6f433f019cdd1e356e32bc1", "id": 7}, {"samples": [{"hash": "hWpCHCJxfj4", "uri": "/contracts/hWpCHCJxfj4#patent-validity", "label": "Sponsored Research Agreement (A.C.T. Holdings, Inc.)", "score": 21.0, "published": true}, {"hash": "8TdbGCZYN6r", "uri": "/contracts/8TdbGCZYN6r#patent-validity", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "1Tf64n1GC8B", "uri": "/contracts/1Tf64n1GC8B#patent-validity", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}], "snippet": "Nothing in this Agreement shall be construed as a warranty or representation by either party as to the validity or scope of any Patent Rights.", "snippet_links": [{"key": "nothing-in-this-agreement", "type": "clause", "offset": [0, 25]}, {"key": "by-either-party", "type": "clause", "offset": [77, 92]}, {"key": "scope-of", "type": "definition", "offset": [115, 123]}, {"key": "patent-rights", "type": "definition", "offset": [128, 141]}], "size": 4, "hash": "fa97104660b1600c79ae9831d05020e7", "id": 8}, {"samples": [{"hash": "jNSVgazQkyY", "uri": "/contracts/jNSVgazQkyY#patent-validity", "label": "Licensing Agreement", "score": 35.5489352172, "published": true}, {"hash": "46hbkrGErX1", "uri": "/contracts/46hbkrGErX1#patent-validity", "label": "Publisher (Licensor) Agreement", "score": 35.0118487185, "published": true}, {"hash": "e3ZVkcKKqoc", "uri": "/contracts/e3ZVkcKKqoc#patent-validity", "label": "Licensing Agreement", "score": 34.9392277821, "published": true}], "snippet": "For purposes of Evaluation, issued patents shall be considered valid and enforceable.", "snippet_links": [{"key": "purposes-of-evaluation", "type": "clause", "offset": [4, 26]}, {"key": "issued-patents", "type": "definition", "offset": [28, 42]}, {"key": "valid-and-enforceable", "type": "clause", "offset": [63, 84]}], "size": 8, "hash": "c63ceb79b5e67ee4a24c5d77a57b690a", "id": 3}, {"samples": [{"hash": "iDU63cH0G9P", "uri": "/contracts/iDU63cH0G9P#patent-validity", "label": "Joint Hiv Barrel Product Commercialization Agreement (StatSure Diagnostic Systems, Inc.)", "score": 21.0, "published": true}, {"hash": "9h4EEtSMNt8", "uri": "/contracts/9h4EEtSMNt8#patent-validity", "label": "Joint Hiv Barrel Product Commercialization Agreement (Chembio Diagnostics, Inc.)", "score": 21.0, "published": true}], "snippet": "Chembio, having investigated and analyzed the SDS Patents, hereby acknowledges that each of the SDS Patents is valid and enforceable.", "snippet_links": [{"key": "sds-patents", "type": "definition", "offset": [46, 57]}, {"key": "valid-and-enforceable", "type": "clause", "offset": [111, 132]}], "size": 4, "hash": "02ab053358ebac2ab3280819a100d80c", "id": 10}, {"samples": [{"hash": "nR1UHUBUIw", "uri": "/contracts/nR1UHUBUIw#patent-validity", "label": "License Agreement (Luna Innovations Inc)", "score": 21.0, "published": true}, {"hash": "iAUfgfAFN7E", "uri": "/contracts/iAUfgfAFN7E#patent-validity", "label": "License Agreement (Luna Innovations Inc)", "score": 21.0, "published": true}], "snippet": "14.1 If, in any proceeding in which the validity, infringement, or priority of invention of any claim of the LICENSED PATENT(S) to LICENSEE is in issue, a judgment or decree is entered which becomes final (below referred to as an \u201cfinal judgment\u201d), the construction placed upon any such claim by such final judgment shall thereafter be followed, not only as to such claim but as to all claims to which such construction applies, with respect to subsequently occurring acts. If such final judgment holds any claim invalid, LICENSEE shall be relieved prospectively (1) from including in its reports ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES sold or otherwise disposed of covered only by such claim or any broader claim to which such final judgment is applicable, and (2) from the performance of those other acts which may be required by this Agreement only because of any such claim. However, if there are two or more conflicting final judgments with respect to the same claim based on the same grounds or where the same issues were raised, the decision of the higher tribunal shall be followed, but if the tribunals be of equal dignity, then the decision more favorable to the claim shall be followed.\n14.2 In the event evidentiary material comes to the attention of the LICENSEE subsequent to the LICENSEE\u2019S execution of this Agreement which, in the judgment of the LICENSEE, bears on the validity or scope of any LICENSED PATENT(S), the LICENSOR will in good faith discuss with the LICENSEE whether such evidentiary material so affects the validity or scope of the LICENSED PATENT(S) to which it is asserted to apply that the terms of the license in respect to such LICENSED PATENT(S) should be modified.\n14.3 The LICENSEE, subsequent to the date of its execution of this Agreement, may assert the invalidity of any claim in any LICENSED PATENT(S), if coupled with or followed by:\n(a) withholding, or notice of intention to withhold, or denial of obligation to pay, royalties otherwise payable under this Agreement in respect to the LICENSEE\u2019S operations under such claim; or\n(b) initiation or participation in a suit challenging or denying the validity of such claim in reference to LICENSEE\u2019S operations under this Agreement, that may, at the option of the LICENSOR, be conclusively presumed to constitute LICENSEE\u2019S termination, as of the earliest provable date of such withholding, notice, denial, initiation, or participation, of its Agreement including its obligation for payment of royalties due from the date of the termination.\n14.4 If an action by a THIRD PARTY requires the LICENSEE to defend its right to practice the LICENSED PATENT(S) pursuant to this Agreement, then LICENSOR may, in its sole discretion, cooperate and assist in all respects and, to the extent possible, make available relevant records, papers, information, samples, models, specimens; and the like.", "snippet_links": [{"key": "to-licensee", "type": "definition", "offset": [128, 139]}, {"key": "in-issue", "type": "definition", "offset": [143, 151]}, {"key": "the-construction", "type": "clause", "offset": [249, 265]}, {"key": "all-claims", "type": "clause", "offset": [382, 392]}, {"key": "with-respect-to", "type": "clause", "offset": [429, 444]}, {"key": "licensee-shall", "type": "clause", "offset": [522, 536]}, {"key": "base-products", "type": "clause", "offset": [605, 618]}, {"key": "base-services", "type": "clause", "offset": [631, 644]}, {"key": "otherwise-disposed-of", "type": "definition", "offset": [653, 674]}, {"key": "the-performance", "type": "clause", "offset": [780, 795]}, {"key": "other-acts", "type": "definition", "offset": [805, 815]}, {"key": "by-this-agreement", "type": "clause", "offset": [838, 855]}, {"key": "final-judgments", "type": "clause", "offset": [934, 949]}, {"key": "based-on", "type": "clause", "offset": [981, 989]}, {"key": "the-decision", "type": "clause", "offset": [1045, 1057]}, {"key": "more-favorable", "type": "definition", "offset": [1160, 1174]}, {"key": "the-claim", "type": "definition", "offset": [1178, 1187]}, {"key": "in-the-event", "type": "clause", "offset": [1212, 1224]}, {"key": "attention-of", "type": "clause", "offset": [1259, 1271]}, {"key": "the-licensee", "type": "clause", "offset": [1272, 1284]}, {"key": "subsequent-to-the", "type": "clause", "offset": [1285, 1302]}, {"key": "execution-of-this-agreement", "type": "clause", "offset": [1314, 1341]}, {"key": "licensor-will", "type": "clause", "offset": [1444, 1457]}, {"key": "in-good-faith", "type": "definition", "offset": [1458, 1471]}, {"key": "scope-of-the", "type": "clause", "offset": [1559, 1571]}, {"key": "to-apply", "type": "clause", "offset": [1615, 1623]}, {"key": "in-respect-to", "type": "clause", "offset": [1654, 1667]}, {"key": "date-of", "type": "clause", "offset": [1749, 1756]}, {"key": "notice-of-intention", "type": "definition", "offset": [1908, 1927]}, {"key": "obligation-to-pay", "type": "clause", "offset": [1954, 1971]}, {"key": "reference-to", "type": "definition", "offset": [2178, 2190]}, {"key": "the-option", "type": "clause", "offset": [2248, 2258]}, {"key": "payment-of-royalties", "type": "clause", "offset": [2485, 2505]}, {"key": "the-termination", "type": "clause", "offset": [2527, 2542]}, {"key": "by-a-third-party", "type": "clause", "offset": [2562, 2578]}, {"key": "licensee-to-defend", "type": "clause", "offset": [2592, 2610]}, {"key": "right-to-practice", "type": "clause", "offset": [2615, 2632]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [2656, 2682]}, {"key": "sole-discretion", "type": "clause", "offset": [2710, 2725]}, {"key": "in-all-respects", "type": "clause", "offset": [2748, 2763]}, {"key": "to-the-extent", "type": "clause", "offset": [2769, 2782]}, {"key": "make-available", "type": "definition", "offset": [2793, 2807]}, {"key": "relevant-records", "type": "definition", "offset": [2808, 2824]}], "size": 10, "hash": "bbe0423786cb01cf7d2b3718947e4f2e", "id": 2}, {"samples": [{"hash": "dMtZnYSDwmf", "uri": "/contracts/dMtZnYSDwmf#patent-validity", "label": "Exclusive Equity Agreement (Medicenna Therapeutics Corp.)", "score": 33.4709103354, "published": true}, {"hash": "4r1NKlPfN0v", "uri": "/contracts/4r1NKlPfN0v#patent-validity", "label": "Exclusive Equity Agreement (Medicenna Therapeutics Corp.)", "score": 33.4709103354, "published": true}, {"hash": "ikF9bpDWAuq", "uri": "/contracts/ikF9bpDWAuq#patent-validity", "label": "Exclusive License Agreement (Kala Pharmaceuticals, Inc.)", "score": 33.2381930185, "published": true}], "snippet": "Any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa \u2587\u2587\u2587\u2587\u2587 County, California, and the parties agree not to challenge personal jurisdiction in that forum.", "snippet_links": [{"key": "licensed-patent", "type": "clause", "offset": [42, 57]}, {"key": "located-in", "type": "definition", "offset": [91, 101]}, {"key": "the-parties-agree", "type": "clause", "offset": [138, 155]}, {"key": "personal-jurisdiction", "type": "definition", "offset": [173, 194]}], "size": 81, "hash": "2b5af779666e32213ec7845509a45685", "id": 1}, {"samples": [{"hash": "dKhrW82kPmS", "uri": "/contracts/dKhrW82kPmS#patent-validity", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}, {"hash": "bb6tjUVeR8K", "uri": "/contracts/bb6tjUVeR8K#patent-validity", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}, {"hash": "aOs8yIYYW0m", "uri": "/contracts/aOs8yIYYW0m#patent-validity", "label": "Strategic Collaboration Agreement (Epix Medical Inc)", "score": 18.0, "published": true}], "snippet": "28 11.2. Accuracy of Exhibits C and E.................................................................. 28 11.3. Authorization................................................................................. 28 11.4. [ ]*.......................................................................................... 29", "snippet_links": [{"key": "exhibits-c-and-e", "type": "clause", "offset": [21, 37]}], "size": 5, "hash": "e01ffa16602922a4434cb7cf159d2875", "id": 6}, {"samples": [{"hash": "3qruouJovwt", "uri": "/contracts/3qruouJovwt#patent-validity", "label": "Exclusive Licence Agreement", "score": 31.340862423, "published": true}, {"hash": "ydHKckhj0g", "uri": "/contracts/ydHKckhj0g#patent-validity", "label": "Exclusive Licence Agreement (Ascendis Pharma a/S)", "score": 28.2511978097, "published": true}, {"hash": "2uZxsXGptds", "uri": "/contracts/2uZxsXGptds#patent-validity", "label": "Exclusive Licence Agreement (Ascendis Pharma a/S)", "score": 28.2511978097, "published": true}], "snippet": "Notwithstanding the other provisions of this Clause 20, any dispute that involves the validity, infringement or claim interpretation of a Patent that is issued: (a) in the United States shall be subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants resides; and (b) in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies. For the sake of clarity, such Patent disputes shall not be subject to the provisions of Clause 20.2. Nothing in this Agreement shall be construed to prevent the Licensee from disputing or challenging the validity of a Third Party\u2019s Patent.", "snippet_links": [{"key": "notwithstanding-the", "type": "definition", "offset": [0, 19]}, {"key": "clause-20", "type": "clause", "offset": [45, 54]}, {"key": "interpretation-of", "type": "clause", "offset": [118, 135]}, {"key": "the-united-states-shall", "type": "clause", "offset": [168, 191]}, {"key": "united-states-patent-and-trademark-office", "type": "clause", "offset": [225, 266]}, {"key": "federal-court", "type": "clause", "offset": [303, 316]}, {"key": "located-in", "type": "definition", "offset": [317, 327]}, {"key": "of-the-district", "type": "clause", "offset": [345, 360]}, {"key": "the-defendants", "type": "clause", "offset": [374, 388]}, {"key": "an-appropriate", "type": "clause", "offset": [451, 465]}, {"key": "administrative-body", "type": "definition", "offset": [480, 499]}, {"key": "court-in", "type": "clause", "offset": [503, 511]}, {"key": "the-parties", "type": "definition", "offset": [530, 541]}, {"key": "consent-to", "type": "clause", "offset": [549, 559]}, {"key": "jurisdiction-and-venue", "type": "clause", "offset": [564, 586]}, {"key": "patent-disputes", "type": "clause", "offset": [644, 659]}, {"key": "subject-to-the-provisions-of-clause", "type": "clause", "offset": [673, 708]}, {"key": "nothing-in-this-agreement", "type": "clause", "offset": [715, 740]}, {"key": "the-licensee", "type": "clause", "offset": [771, 783]}, {"key": "a-third-party", "type": "clause", "offset": [830, 843]}], "size": 5, "hash": "767fdd42ecc353d74690e41bd21ec86c", "id": 4}, {"samples": [{"hash": "11Mtym6Ly3L", "uri": "/contracts/11Mtym6Ly3L#patent-validity", "label": "Platform Agreement", "score": 31.340862423, "published": true}, {"hash": "3WSKbhvHdMv", "uri": "/contracts/3WSKbhvHdMv#patent-validity", "label": "Platform Agreement (Cerulean Pharma Inc.)", "score": 25.0793976728, "published": true}, {"hash": "8Sep8ak1B6r", "uri": "/contracts/8Sep8ak1B6r#patent-validity", "label": "Platform Agreement (Arrowhead Research Corp)", "score": 21.0, "published": true}], "snippet": "To Calando\u2019s Knowledge, (i) all issued patents included in the Collective Patent Rights are valid and enforceable; (ii) no claim has been made against Calando, its Affiliates or the Third Party co-owner thereof alleging that any issued patent included in the Collective Patent Rights is invalid or unenforceable; (iii) all assignments of such Patent Rights have been properly executed and recorded; (iv) all issuance, renewal, maintenance and other payments that are or have become due with respect thereto have been timely paid by or on behalf of Calando or the Third Party co-owner thereof; (v) there are no inventorship challenges, opposition or nullity proceedings or interferences declared, commenced or provoked with respect to any Collective Patent Rights; and (vi) with respect to the Assigned Patent Rights and with respect to any Licensed Patent Rights owned, in whole or in part, by Calando, Calando and its Affiliates have, and any co-owner of such Patent Rights has, complied with the duty of candor and disclosure to the United States Patent and Trademark Office and any relevant foreign patent office and have made no material misrepresentation in any patent applications included in or underlying such Patent Rights. Calando has no Knowledge of any information that would preclude it from owning the Assigned IP (immediately prior to the assignment pursuant to Section 2.2) or the Licensed Patent Rights described in clause (vi) hereof.", "snippet_links": [{"key": "issued-patents", "type": "definition", "offset": [32, 46]}, {"key": "collective-patent-rights", "type": "definition", "offset": [63, 87]}, {"key": "valid-and-enforceable", "type": "clause", "offset": [92, 113]}, {"key": "no-claim", "type": "definition", "offset": [120, 128]}, {"key": "the-third-party", "type": "definition", "offset": [178, 193]}, {"key": "invalid-or-unenforceable", "type": "clause", "offset": [287, 311]}, {"key": "properly-executed", "type": "definition", "offset": [367, 384]}, {"key": "maintenance-and", "type": "clause", "offset": [427, 442]}, {"key": "other-payments", "type": "definition", "offset": [443, 457]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [529, 547]}, {"key": "with-respect-to", "type": "clause", "offset": [718, 733]}, {"key": "assigned-patent-rights", "type": "clause", "offset": [793, 815]}, {"key": "licensed-patent-rights", "type": "clause", "offset": [840, 862]}, {"key": "duty-of-candor", "type": "clause", "offset": [998, 1012]}, {"key": "united-states-patent-and-trademark-office", "type": "clause", "offset": [1035, 1076]}, {"key": "patent-office", "type": "definition", "offset": [1102, 1115]}, {"key": "no-material-misrepresentation", "type": "clause", "offset": [1130, 1159]}, {"key": "patent-applications", "type": "definition", "offset": [1167, 1186]}, {"key": "knowledge-of", "type": "clause", "offset": [1248, 1260]}, {"key": "assigned-ip", "type": "definition", "offset": [1316, 1327]}, {"key": "the-assignment", "type": "clause", "offset": [1350, 1364]}, {"key": "section-22", "type": "clause", "offset": [1377, 1388]}, {"key": "the-licensed-patent", "type": "clause", "offset": [1393, 1412]}, {"key": "rights-described", "type": "clause", "offset": [1413, 1429]}, {"key": "in-clause", "type": "clause", "offset": [1430, 1439]}], "size": 5, "hash": "dd86601c516bc5e1eeb95f89fc2289a1", "id": 5}, {"samples": [{"hash": "gYICoiiyVl8", "uri": "/contracts/gYICoiiyVl8#patent-validity", "label": "Exclusive Patent License Agreement", "score": 26.3456536619, "published": true}, {"hash": "7ia4AEhfOPK", "uri": "/contracts/7ia4AEhfOPK#patent-validity", "label": "Exclusive Patent License Agreement", "score": 25.9609856263, "published": true}, {"hash": "8qkIU17MDgI", "uri": "/contracts/8qkIU17MDgI#patent-validity", "label": "Exclusive Patent License Agreement", "score": 23.2176591376, "published": true}], "snippet": "16.1 If any claim challenging the validity or enforceability of any of Patent Rights will be brought against Licensee, Licensee will promptly notify University. University, at its option, will have the right, within thirty (30) days after notification by Licensee of such action, to intervene and take over the sole defense of the claim at University\u2019s expense.\n16.2 If Licensee or third party challenges the validity or enforceability of any of Patent Rights, Licensee will not suspend any payments due University until such time as the Patent Rights are determined to be invalid or unenforceable by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken.", "snippet_links": [{"key": "patent-rights", "type": "definition", "offset": [71, 84]}, {"key": "licensee-will", "type": "clause", "offset": [119, 132]}, {"key": "promptly-notify", "type": "clause", "offset": [133, 148]}, {"key": "the-right", "type": "clause", "offset": [198, 207]}, {"key": "within-thirty", "type": "clause", "offset": [209, 222]}, {"key": "after-notification", "type": "clause", "offset": [233, 251]}, {"key": "by-licensee", "type": "clause", "offset": [252, 263]}, {"key": "the-claim", "type": "definition", "offset": [327, 336]}, {"key": "third-party-challenges", "type": "clause", "offset": [382, 404]}, {"key": "payments-due", "type": "clause", "offset": [491, 503]}, {"key": "the-patent", "type": "definition", "offset": [534, 544]}, {"key": "invalid-or-unenforceable", "type": "clause", "offset": [573, 597]}, {"key": "final-judgment", "type": "definition", "offset": [603, 617]}, {"key": "court-of-competent-jurisdiction", "type": "definition", "offset": [623, 654]}, {"key": "no-appeal", "type": "clause", "offset": [666, 675]}], "size": 4, "hash": "88c8f0b3ab404d9293faa3559b037e7b", "id": 9}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhhwYXRlbnQtdmFsaWRpdHkjMDAwMDAwMGEMogECZW4YACAA", "clause": {"children": [["choice-of-law", "Choice of Law"], ["all-notices", "All Notices"], ["exclusive-forum", "Exclusive Forum"], ["headings", "Headings"], ["waiver", "Waiver"]], "title": "Patent Validity", "size": 213, "parents": [["dispute-resolution", "Dispute Resolution"], ["representations-and-warranties", "Representations and Warranties"], ["export", "EXPORT"], ["abandonment-of-suit", "Abandonment of Suit"], ["miscellaneous", "Miscellaneous"]], "id": "patent-validity", "related": [["infringement-and-patent-enforcement", "INFRINGEMENT AND PATENT ENFORCEMENT", "INFRINGEMENT AND PATENT ENFORCEMENT"], ["copyright-infringement", "Copyright Infringement", "Copyright Infringement"], ["patent-infringement", "Patent Infringement", "Patent Infringement"], ["licensed-patents", "Licensed Patents", "Licensed Patents"], ["patent-rights", "Patent Rights", "Patent Rights"]], "related_snippets": [], "updated": "2025-07-07T12:37:39+00:00", "also_ask": ["What drafting elements are essential to ensure robust patent validity protection?", "How can this clause be leveraged to shift the burden of proof in litigation?", "What are the most common pitfalls that render a patent validity clause unenforceable?", "How does this clause compare to industry standards or statutory requirements?", "What factors do courts consider when assessing the enforceability of a patent validity clause?"], "drafting_tip": null, "explanation": "The Patent Validity clause establishes the parties' positions and obligations regarding the enforceability and legitimacy of any patents referenced or licensed under the agreement. Typically, this clause addresses what happens if a patent is found to be invalid or unenforceable, such as whether royalty payments continue or if the agreement is terminated. Its core function is to allocate risk and clarify the consequences of a patent's invalidity, thereby protecting both parties from unforeseen legal or financial exposure related to patent rights."}, "json": true, "cursor": ""}}